A Bigger Event Than Normal

Insmed, a small/mid-cap biotech focusing on rare diseases, is hosting an R&D day event on September 30th. After absorbing a common stock offering last May remarkably well, shares of the niche biotech firm spent all of this summer basing tightly sideways. 

Recently, INSM shot up on heavy buy volume (right-hand bottom pane of the daily chart, below). 

With price breaking out on heavy buy volume from multi-month tight range, combined with the GILD for IMMU fat premium buyout, I view INSM as one of several prime candidates to continue a possible biotech bonanza of M&A deals into the end of 2020. And with some uncertainty regarding the upcoming Election, those deals may get done sooner rather than later--After all, once we get even close to Thanksgiving we could easily see these deals get put on the shelf until a few weeks into 2021, and then who knows what will happen?

Moreover, with INSM being so specialized in biotech regarding rare diseases, the R&D day should count for more than usual as for the firm gaining exposure and analyst insights.